Physician profile
Sumayah Jamal
NPI 1487643516
$6,526.79
in general payments reported to CMS, 2019-2025
24 companies · $1,844 in 2025
The $1,844 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $299 · 2021: $423 · 2022: $603 · 2023: $1,287 · 2024: $1,407 · 2025: $1,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,367 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,366.86 |
| Education | $171.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $879.41 | 2019-2025 | Tremfya |
| Abbvie INC. | $850.86 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $599.74 | 2019-2025 | |
| Incyte Corporation | $586.68 | 2021-2025 | Opzelura |
| Genzyme Corporation | $532.53 | 2022-2025 | |
| Pfizer INC. | $437.28 | 2019-2025 | |
| Lilly USA, LLC | $395.27 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $339.83 | 2019-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $315.32 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $252.37 | 2019-2025 | Jublia, Cabtreo |
| Amgen INC. | $228.35 | 2022-2024 | Otezla |
| Galderma Laboratories, L.P. | $204.93 | 2023-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $194.12 | 2019-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $193.16 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $189.91 | 2019-2025 | Absorica Ld, Winlevi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $77.66 | 2022-2024 | Bimzelx |
| Journey Medical Corporation | $59.19 | 2021-2025 | |
| Almirall LLC | $40.83 | 2019-2022 | |
| Epi Health, LLC | $37.52 | 2019-2020 | |
| Botanix Sb INC | $35.93 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.02 | 2024 | Cyltezo |
| Dermira, INC. | $19.04 | 2020 | |
| Sandoz INC. | $14.37 | 2019 | |
| Strata Skin Sciences, INC. | $13.47 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumayah Jamal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.